Medical device company Apyx Medical Corporation (NASDAQ:APYX) stated on Monday that it expects total revenue in a range of USD16.3 to USD16.8m for the fourth quarter ended 31 December 2021.

This marks a growth of 42% to 46% in total revenues year-over-year.

For the fourth quarter ended 31 December 2021, the company anticipates Advanced Energy revenue in the USD14.7 to USD15.0m range, representing growth of 49% to 52% year-over-year. OEM revenue in the USD1.5 to USD1.7m range, down 2% year-over-year to growth of 10% year-over-year.

The company expects total revenue in a range of USD48.0 to USD48.5m for the full year 2021, a rise of 73% to 75% year-over-year.

In addition, the company expects Advanced Energy revenue in a range of USD42.7 to USD43.0m, an increase of approximately 92% to 93% year-over-year. OEM revenue in a range of USD5.3 to USD5.5m, a dip of 4% to 0% year-over-year.